Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 253

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 253
---
 with the Chairman, taking account of the agendas for the meetings of the specialist Committees and the suggestions of the directors. Approximately one week prior to each meeting of the Board of Directors, the directors each receive a file containing the agenda, the minutes of the previous meeting, and documentation relating to the agenda. The minutes of each meeting are expressly approved at the next meeting of the Board of Directors. In compliance with our Board Charter, certain issues are examined in advance by the various Committees according to their areas of competence, to enable them to make a recommendation; those issues are then submitted for a decision by the Board of Directors. Since 2016, acting on a recommendation from the Appointments, Governance and CSR Committee, each year the Board has held at least two executive sessions, i.e. meetings held without the Chief Executive Officer present. If the Chairman of the Board so decides, such sessions may also be held without the directors representing employees (or any other Sanofi employee) being present. The primary purpose of such sessions is to evaluate the way the Board and its Committees operate, discuss the performance of the Chief Executive Officer, and debate succession planning. Three executive sessions were held in 2024: two one-hour sessions in January and February, and a 20-minute session in April.

| 148 | SANOFIFORM 20-F2024 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

In 2024, the main activities of the Board of Directors related to the following issues:

| FINANCIAL STATEMENTS AND FINANCIAL MANAGEMENT |                                                                                                                                                                                                                                                                                                                                                    |
| l                                             | Review of the individual company and consolidated financial statements for the 2023 financial year and for the first half of 2024, review of theconsolidated financial statements for the first three quarters of 2024, and review of draft press releases and presentations to analysts relating tothe publication of those financial statements. |
| l                                             | Projected 2024 accounting close, presentation of 2025 budget and 2025-2027 financial forecasts.                                                                                                                                                                                                                                                    |
| l                                             | Review of forward-looking management documents.                                                                                                                                                                                                                                                                                                    |
| l                                             | Proposed dividend for the 2023 financial year.                                                                                                                                                                                                                                                                                                     |
| l                                             | Renewal of share repurchase program.                                                                                                                                                                                                                                                                                                               |
| l                                             | Formally recording the share capital, and amending the Articles of Association accordingly.                                                                                                                                                                                                                                                        |
| l                                             | Delegation to the Chief Executive Officer of the power to issue